There is no question we live in very strange times. Yesterday JNJ reported earnings and this was not a diabetes event. This morning Abbott reported results, and this was a major diabetes event. Even stranger and we’d recommend sitting down for this are we are about to say some very nice things about Abbott.
As we have noted before Libre has exceeded everyone’s expectations and continues to do so. However, given Abbott’s history- remember they have run not one but two BGM companies into the ground and before Libre had a dubious history in CGM, we worried . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.